Bayer

Consecutive Use of Gilenya and Lemtrada Causes Disease Activity in MS Patient, Case Report Suggests

Multiple sclerosis (MS) patients may experience severe disease exacerbation after switching from Novartis’ Gilenya (fingolimod) to Sanofi Genzyme’s Lemtrada (alemtuzumab), a case report suggests. This unexpected high disease activity raises questions about managing MS through the consecutive use of immunotherapies. The case report, “Unexpected high multiple…

What’s Hot and What’s Not Among MS Therapies?

The newest kids on the MS block, disease-modifying therapies (DMT) such as Genentech’s Ocrevus (ocrelizumab) and Sanofi Genzyme’s Lemtrada (alemtuzumab), are attracting a lot of interest these days. But, some DMTs that have been around for more than two decades are still being prescribed by a lot of neurologists.

FDA Approves Two Bayer Products to Help MS Patients Stay on Top of Interferon Injections

The U.S. Food and Drug Administration has approved a supplemental biologics license application for two Bayer products that help multiple sclerosis patients keep track of their injections of Betaseron (interferon beta-1b). The products are the myBETAapp and the Betaconnect Navigator software. A biologics license application is a request for permission to market…

#CMSC16 – Interview with Bayer’s VP and General Manager on Betaconnect/Betaseron and Customized Therapy

Global pharma Bayer Healthcare aims to improve human health by diagnosing, preventing, and treating a variety of diseases. The company currently provides products for general medicine, hematology, neurology, oncology, and women’s healthcare. In 1993, Bayer’s Betaseron (interferon beta-1b) became the first disease-modifying drug to be approved by the U.S. Food and Drug Administration (FDA) for…

FDA Approves BETACONNECT Autoinjector for BETASERON Delivery

Bayer HealthCare is pleased to announce the US Food and Drug Administration (FDA) has granted the approval of BETACONNECT, a first-of-its-kind electronic autoinjector indicated as a treatment for relapsing-remitting multiple sclerosis (RRMS). For now, the drug delivery device is only compatible with BETASERON® (interferon beta-1b), and will soon be available come early 2016.  While…

11-Year Follow-up of Bayer’s BENEFIT Interferon-beta1b Treatment Reveals Positive Results For MS Patients

Results from the BENEFIT11 trial indicate that early treatment with IFNB-1b leads to improvements in cognition and fatigue in the long-term, as well as sustained employment and favorable magnetic resonance imaging (MRI) outcomes, measured at the 11-year mark. Supported by Bayer HealthCare Pharmaceuticals, the study, titled “Long-term Impact of Early MS Treatment with…

FDA Accepts Bayer’s BETACONNECT License Application for Relapsing-Remitting Multiple Sclerosis

Bayer HealthCare recently announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a supplemental Biologics License Application (sBLA) for BETACONNECT for the treatment of relapsing-remitting multiple sclerosis (MS). BETACONNECT is a new drug delivery option for patients under Bayer’s BETASERON® (interferon beta-1b) therapy. MS is a…